Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Central Nervous System Neoplasms 2Optic Nerve Glioma 1Neurofibromatosis 1 1Medulloblastoma 1Glioma 1Ependymoma 1Brain Neoplasms 1

Interventions

Radiotherapy 122Temozolomide 110Carboplatin 53Filgrastim 46Vincristine 43Etoposide 39Cyclophosphamide 37Chemotherapy, Adjuvant 37Cisplatin 36Carmustine 32Irinotecan 27Peripheral Blood Stem Cell Transplantation 25Magnetic Resonance Spectroscopy 24Lomustine 22Thiotepa 21Methotrexate 20Granulocyte Colony-Stimulating Factor 18Procarbazine 16Bevacizumab 16Surgical Procedures, Operative 15O(6)-benzylguanine 14etoposide phosphate 13Drug Therapy 13Topotecan 12Paclitaxel 12Ifosfamide 12Thalidomide 11Radiation 11sargramostim 10Specimen Handling 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × pomalidomide × CNS × Clear all
NCT03257631 2024-04-16

A Study of Pomalidomide Monotherapy for Children and Young Adults With Recurrent or Progressive Primary Brain Tumors

Celgene

Phase 2 Completed
53 enrolled 18 charts
CNS

Brain Neoplasms, Ependymoma, Glioma, Medulloblastoma, Central Nervous System Neoplasms

NCT02415153 2022-04-25

Pomalidomide in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

National Cancer Institute (NCI)

Phase 1 Completed
29 enrolled
CNS

Neurofibromatosis 1, Central Nervous System Neoplasms, Optic Nerve Glioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡